guest ::
| Home > Workflow collections > Public records > The Amyloid-β Oligomer Count in Cerebrospinal Fluid is a Biomarker for Alzheimer's Disease > print |
| Home > Workflow collections > Public records > The Amyloid-β Oligomer Count in Cerebrospinal Fluid is a Biomarker for Alzheimer's Disease > print |
| 001 | 133640 | ||
| 005 | 20210131025857.0 | ||
| 024 | 7 | _ | |a 10.3233/JAD-122047 |2 doi |
| 024 | 7 | _ | |a WOS:000316464700016 |2 WOS |
| 024 | 7 | _ | |a 2128/5096 |2 Handle |
| 024 | 7 | _ | |a altmetric:21820148 |2 altmetric |
| 024 | 7 | _ | |a 23313925 |2 pmid |
| 037 | _ | _ | |a FZJ-2013-02055 |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Wang-Dietrich, Lei |0 P:(DE-Juel1)132027 |b 0 |
| 245 | _ | _ | |a The Amyloid-β Oligomer Count in Cerebrospinal Fluid is a Biomarker for Alzheimer's Disease |
| 260 | _ | _ | |a Amsterdam |c 2013 |b IOS Press |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 133640 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a article |2 DRIVER |
| 500 | _ | _ | |3 POF3_Assignment on 2016-02-29 |
| 520 | _ | _ | |a Recent studies indicate that small amyloid-β peptide (Aβ) oligomers are the major toxic species responsible for development and progression of Alzheimer's disease (AD). Therefore, we suggest that the number of Aβ oligomers in body fluids is the most direct and relevant biomarker for AD. Determination of the Aβ oligomer content of cerebrospinal fluid (CSF) samples from 14 AD patients and 12 age-matched controls revealed a clear distinction between both groups. All samples of the control group showed homogenously low numbers of Aβ oligomers, while the samples of the AD group exhibited significantly higher levels of Aβ oligomers. The Aβ oligomer numbers correlated with the patients' Mini-Mental State Examination scores. This indicates that the quantity of Aβ oligomers in CSF reflects the severity of the disease and that Aβ oligomers play a crucial role in AD pathology and in turn can be used as a diagnostic biomarker. |
| 536 | _ | _ | |a 452 - Structural Biology (POF2-452) |0 G:(DE-HGF)POF2-452 |c POF2-452 |f POF II |x 0 |
| 536 | _ | _ | |a 331 - Signalling Pathways and Mechanisms in the Nervous System (POF2-331) |0 G:(DE-HGF)POF2-331 |c POF2-331 |f POF II |x 1 |
| 700 | 1 | _ | |a Funke, Aileen |0 P:(DE-Juel1)131999 |b 1 |
| 700 | 1 | _ | |a Kühbach, Katja |0 P:(DE-Juel1)145440 |b 2 |
| 700 | 1 | _ | |a Wang, Kun |0 P:(DE-Juel1)144117 |b 3 |
| 700 | 1 | _ | |a Besmehn, Astrid |0 P:(DE-Juel1)133839 |b 4 |
| 700 | 1 | _ | |a Willbold, Sabine |0 P:(DE-Juel1)133857 |b 5 |
| 700 | 1 | _ | |a Cinar, Yeliz |0 P:(DE-Juel1)131993 |b 6 |
| 700 | 1 | _ | |a Bannach, Oliver |0 P:(DE-Juel1)157832 |b 7 |
| 700 | 1 | _ | |a Birkmann, Eva |0 P:(DE-Juel1)131992 |b 8 |
| 700 | 1 | _ | |a Willbold, Dieter |0 P:(DE-Juel1)132029 |b 9 |e Corresponding author |
| 773 | _ | _ | |a 10.3233/JAD-122047 |0 PERI:(DE-600)2070772-1 |n 4 |p 985-994 |t Journal of Alzheimer's disease |v 34 |x 1387-2877 |
| 856 | 4 | _ | |y Publishers version according to licensing conditions. |z Published final document. |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/133640/files/FZJ-2013-02055.pdf |y OpenAccess |z Published final document. |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/133640/files/FZJ-2013-02055.jpg?subformat=icon-1440 |x icon-1440 |y OpenAccess |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/133640/files/FZJ-2013-02055.jpg?subformat=icon-180 |x icon-180 |y OpenAccess |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/133640/files/FZJ-2013-02055.jpg?subformat=icon-640 |x icon-640 |y OpenAccess |
| 909 | _ | _ | |p VDB |o oai:juser.fz-juelich.de:133640 |
| 909 | _ | _ | |p VDB |o oai:juser.fz-juelich.de:133640 |
| 909 | _ | _ | |p VDB |o oai:juser.fz-juelich.de:133640 |
| 909 | C | O | |o oai:juser.fz-juelich.de:133640 |p openaire |p open_access |p driver |p VDB |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)132027 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)131999 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)145440 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)144117 |
| 910 | 1 | _ | |a Analytik |0 I:(DE-Juel1)ZEA-3-20090406 |k ZEA-3 |b 4 |6 P:(DE-Juel1)133839 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)133839 |
| 910 | 1 | _ | |a Analytik |0 I:(DE-Juel1)ZEA-3-20090406 |k ZEA-3 |b 5 |6 P:(DE-Juel1)133857 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)133857 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 6 |6 P:(DE-Juel1)131993 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 7 |6 P:(DE-Juel1)157832 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 8 |6 P:(DE-Juel1)131992 |
| 910 | 1 | _ | |a Forschungszentrum Jülich GmbH |0 I:(DE-588b)5008462-8 |k FZJ |b 9 |6 P:(DE-Juel1)132029 |
| 913 | 2 | _ | |a DE-HGF |b Key Technologies |l BioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences |1 G:(DE-HGF)POF3-550 |0 G:(DE-HGF)POF3-559H |2 G:(DE-HGF)POF3-500 |v Addenda |x 0 |
| 913 | 2 | _ | |a DE-HGF |b Key Technologies |l Decoding the Human Brain |1 G:(DE-HGF)POF3-570 |0 G:(DE-HGF)POF3-579H |2 G:(DE-HGF)POF3-500 |v Addenda |x 1 |
| 913 | 1 | _ | |a DE-HGF |b Schlüsseltechnologien |1 G:(DE-HGF)POF2-450 |0 G:(DE-HGF)POF2-452 |2 G:(DE-HGF)POF2-400 |v Structural Biology |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF2 |l BioSoft |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Funktion und Dysfunktion des Nervensystems |1 G:(DE-HGF)POF2-330 |0 G:(DE-HGF)POF2-331 |2 G:(DE-HGF)POF2-300 |v Signalling Pathways and Mechanisms in the Nervous System |x 1 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF2 |
| 914 | 1 | _ | |y 2013 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial CC BY-NC 3.0 |0 LIC:(DE-HGF)CCBYNC3 |2 HGFVOC |
| 915 | _ | _ | |a Peer review unknown |0 StatID:(DE-HGF)0040 |2 StatID |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Thomson Reuters Master Journal List |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 920 | 1 | _ | |0 I:(DE-Juel1)ICS-6-20110106 |k ICS-6 |l Strukturbiochemie |x 0 |
| 920 | 1 | _ | |0 I:(DE-Juel1)ZEA-3-20090406 |k ZEA-3 |l Analytik |x 1 |
| 980 | 1 | _ | |a FullTexts |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a JUWEL |
| 980 | _ | _ | |a FullTexts |
| 980 | _ | _ | |a I:(DE-Juel1)ICS-6-20110106 |
| 980 | _ | _ | |a I:(DE-Juel1)ZEA-3-20090406 |
| 980 | _ | _ | |a VDB |
| 981 | _ | _ | |a I:(DE-Juel1)IBI-7-20200312 |
| 981 | _ | _ | |a I:(DE-Juel1)ZEA-3-20090406 |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|